ENDRA Life Sciences Inc.
NDRA
$3.98
$0.529915.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -184.28% | 24.08% | 12.82% | 5.68% | 55.63% |
| Total Depreciation and Amortization | -24.18% | -23.30% | -31.09% | -21.55% | -9.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 474.56% | 245.79% | -81.05% | 97.64% | 41.51% |
| Change in Net Operating Assets | 117.74% | -229.07% | 218.00% | -16.38% | -648.30% |
| Cash from Operations | 30.30% | 36.23% | 8.17% | 14.46% | 29.59% |
| Capital Expenditure | 100.00% | -- | -- | 0.00% | 82.12% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | -- | -- | 11.85% | 105.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | 55.71% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -99.85% | 55.05% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -202.78% | -11.49% | 113.70% | 32.94% | 83.99% |